Focus: Teva is a global pharmaceutical company headquartered in Israel with a portfolio spanning small molecules and biologics across neurology, cardiovascular, oncology, and immunology. A large-cap public company with ~$14.9B in annual revenue (FY2024), Teva operates as both an innovator and generic manufacturer.
Profile data last refreshed 20h ago · AI intelligence enriched 2w ago
2 recent layoff filings (12 mo) — 259 affected
Source: state DOL filings via Big Local News
No open roles listed right now. Follow Teva to get notified when they start hiring — the background below is worth knowing for when they do.
Help build intelligence for Teva
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Teva's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Flagship franchise representing 32% of total revenue; extended-release formulation (AUSTEDO XR, $91M) extends lifecycle to 2041.
Second-largest product by revenue but facing generic/biosimilar pressure; transition imminent, creating near-term revenue headwind.
Solid specialty pain asset with extended LOE; benefits from opioid-use-disorder market tailwinds.
Generic erosion underway; represents significant patent cliff risk in near to medium term.
2720 discontinued, 856 duplicate formulations not shown
+28 more products with revenue data
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
Active shortages (Adderall, methylphenidate, hydroxocobalamin) on Teva products raise supply-chain/manufacturing red flags; no recent WARN filings visible, but operational strain evident.
+476 more products
+1 more
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo